MCIR1: A patient-derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance.

Xiaosheng WuKevin E NowakowskiJithma P AbeykoonMichelle ManskeMary J StensonMichael M TimmCurtis A HansonDaniel L Van DykeSurendra DasariThomas E Witzig

Published in: European journal of haematology (2021)

We have established the first patient-derived ibrutinib-resistant MCL cell line MCIR1 that lacks BTK or PLCγ2 mutations but exhibits a hyperactive non-canonical NF-kB pathway. We further demonstrate its utility in the discovery and validation of new drugs to overcome this resistance.

Keyphrases

chronic lymphocytic leukemia
signaling pathway
small molecule
tyrosine kinase
oxidative stress
lps induced
high throughput
nuclear factor
cell proliferation
immune response
inflammatory response
toll like receptor